221 CRESCENT STREET, WALTHAM, MA
Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
2026 Annual Meeting Results; Directors Elected and Proposals Approved
Viridian Therapeutics Completes $55.1 Million Loan Payoff
Commercial Manufacturing Services Agreement with WuXi Biologics
Viridian Therapeutics Completes $250 Million Convertible Notes Offering
Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Investor Presentation
Q2
Q1
FY 2024
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Prospectus filed pursuant to Rule 305(b)(2)